Willow Tirzepatide Review

Willow—found at startwillow.com—has differentiated itself in the GLP-1 market with flat, all-inclusive pricing and accessible eligibility. Our research (updated July 24, 2026) found a platform with clear per-product pricing, honest FDA disclaimers, and a genuinely mixed independent review record that buyers should read before enrolling.

Three Products, Flat Pricing

Willow's menu and pricing, verified from its own product pages:

• Semaglutide Plus injection (weekly, compounded with Vitamin B12)—$299/month
• Tirzepatide Plus injection (weekly, may include supportive ingredients like B12)—$399/month
• Semaglutide tablets (daily sublingual, dissolved under the tongue)—$299/month

All plans include the prescription, same-day approval, free 2-day shipping, batch quality testing, 24/7 support, and free regular follow-ups from the care team. HSA/FSA payments are accepted with no insurance required. The all-inclusive model means the listed price covers medicine, clinical support, and shipping.

Availability: Check Your State

Willow is not available nationwide. As of our July 2026 check it does not serve residents of Alabama, Alaska, Arkansas, Delaware, Kansas, Louisiana, Maine, Massachusetts, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, or Wyoming—roughly 32 states are served, with eligibility confirmed during signup. The list can change, so the health assessment is the authoritative check.

What Independent Reviews Show

Willow's Trustpilot profile stands at roughly 3.6 stars across 300+ reviews as of July 2026—a genuinely mixed record. Positive reviews consistently cite fast approval, simple flat pricing, responsive shipping, and real results on the injectables (individual reviewers report losses from 12 to 35 lbs over several months—individual anecdotes, not averages). Negative reviews concentrate on weaker results with the oral tablets, billing and refund experiences, and support depth during busy periods. More seriously, several reviewers accuse Willow's advertising of using stock images presented as customer results—an allegation we can't confirm, but one more reason to base your decision on the written terms and the medication facts rather than transformation imagery.

Critical 2026 Regulatory Context

In 2026 the FDA proposed excluding semaglutide and tirzepatide from the 503B bulks list, restricting mass GLP-1 compounding. Confirm current availability and sourcing with Willow before enrolling.

Important: Compounded Medications

Willow's own disclaimers are unusually direct, and worth quoting: its products are compounded medications prepared by licensed compounding pharmacies, "not approved by the U.S. Food and Drug Administration (FDA)," have "not undergone clinical trials to evaluate their safety, efficacy, or therapeutic equivalence," and "are not substitutes for FDA-approved medications" like Wegovy, Ozempic, Mounjaro, or Zepbound. Willow is not the manufacturer and has no affiliation with Novo Nordisk or Eli Lilly. Use only under medical supervision.